The College has been awarded £840,000 from the MRC ‘Confidence in Concept’ scheme to pump–prime the translation of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies toward clinical testing within the Imperial Academic Health Sciences Centre (AHSC). Included in this award is a ring-fenced fund of £125,000 for projects addressing the aims of the Global Challenges Research Fund.
Together with support from the NIHR Imperial BRC, The Royal Marsden Hospital Foundation Trust, Chelsea & Westminster Hospital NHS Foundation Trust and the Imperial College Wellcome Trust Institutional Strategic Support Fund (ISSF), and the Imperial EPSRC Impact Acceleration Account, these schemes create a project-managed ICiC fund in excess of £1.6M to identify early targets, not currently being developed, within the Faculties of Medicine, Natural Sciences and Engineering, to enter into the drug, devices and diagnostics development pathway.
2017 ICiC call for expressions of interest
Applications are now being accepted for ICiC. For information regarding this call, please visit the ICiC webpage.
Completed Expressions of Interest should be sent to Dr Susie Gray (email@example.com) before the deadline of 12.00, Monday 3 April 2017.
Two ICiC events will take place in March to showcase previously funded ICiC projects and for colleagues to find out about this year’s scheme. The Hammersmith event will take place on Thursday 2 March, with the second event at South Kensington on Thursday 9 March. Representatives from MRC, Apollo Therapeutics, Astra Zeneca, Domainex and Pfizer will be in attendance. If you wish to meet with any of these representatives, please contact Dr Susie Gray (firstname.lastname@example.org) in advance of the event.
To register for these events please use the links below: